Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

Size: px

Start display at page:

Download "Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2"

Jeffery Hamilton
5 years ago
Views:

Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks

1 Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to our Sponsors: School of Public Health, University at Albany NYS Department of Health NYS Community Health Partnership Milestones in Public Health Grant from Pfizer, Inc. Special Thanks to NYS Association of County Health Officials NYS Nurses Association Viewer Call-In Phone: Fax: Evaluations Please visit to fill out your evaluation and post test. Nursing Contact Hours, CME, CHES are available. Thank you! 1

Diabetes and Kidney Disease Diabetes is the most common cause of kidney disease. Awareness of CKD is low. Use of CKD tests is low.

2 What are the Kidneys? 1. Two bean shaped organs 2. Each about the size of your fist. Located in the flanks, just below the rib cage 4. Weight is about 1 % of the total body weight, yet 2 % or so of blood flow. Thus, kidneys are efficient filtration organs. Chronic Kidney Disease What is Chronic Kidney Disease? Diabetes and Kidney Disease Diabetes is the most common cause of kidney disease. Awareness of CKD is low. Use of CKD tests is low. Outcomes of CKD include loss of kidney function, complications, kidney failure and death. Early Detection allows more time for interventions to prevent or delay complications and slow loss of kidney function. Vignette Without Early Identification 42-year-old African-American obese man presented to the hospital for treatment of left lower extremity cellulitis, a skin infection. The past history was remarkable for 18 years of diabetes, treated with insulin and complicated by neuropathy, retinopathy, and hypertension. Left ankle Charcot joint was followed by orthopedics for several years. He received laser treatments to both eyes for diabetic retinopathy. Vignette Without Early Identification There was a family history of CKD in his mother, who also has diabetes. Physical exam: BP 12/92, P=8 and regular. Heart and lung examinations were normal. There was + peripheral edema. The left calf was warm, erythematous, and tender. Vignette Without Early Identification Urinary albumin-creatinine ratio > mg/g Serum creatinine 6.2 mg/dl Estimated GFR 1 ml/min/1.7 m 2 by simplified MDRD formula Chronic Kidney Disease: Stage 2

Vignette Summary without Early Evaluation 42-year-old African-American man with Stage CKD Diabetic Kidney Disease. The course of the illness was likely over several years.

Vignette Summary without Early Evaluation This patient is now faced with dialysis and transplant preparation. There is a better way!

3 Vignette Summary without Early Evaluation 42-year-old African-American man with Stage CKD Diabetic Kidney Disease. The course of the illness was likely over several years. There were many opportunities to diagnose and treat CKD over an 18-year course of type-1 diabetes. Vignette Summary without Early Evaluation This patient is now faced with dialysis and transplant preparation. There is a better way! Early identification allows more time for interventions to prevent or delay complications and slow loss of kidney function Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan 1. The CKD burden is high. 2. The CKD burden is unfairly distributed.. Upstream measures could reduce the burden. 4. Preventative strategies are not yet in place. Schoolwerth AC, et al: Prev Chronic Dis :A7, 26 Public Perceptions of Kidney Disease Life Magazine November 1962 Why Chronic Kidney Disease? The word kidney is widely understood by lay people. CKD is a uniform term with specific criteria for diagnosis and classification. Avoid semantics of chronic renal insufficiency, predialysis, etc. Kidney failure (ESRD) for precision and patient acceptance. You can t find what you are not looking for. Yogi Berra

CKD Identification Structural or functional abnormalities of the kidneys for > months, as manifested by either: Urinary albumin-creatinine Ratio > mg/g egfr <6 ml/min/1.

dialysis GFR (ml/min/1.7 2 ) 9 6-89 -9 1-29 <1 US Prevalence in Millions.6* 6.* 1.*.7*.

Diabetes Hypertension Glomerulonephritis HTN 7% 16% Polycystic Kidney Disease Other 19% 4% CKD Diabetes is the Predominant Cause of Kidney Failure US Renal Data System 2 Annual

4 CKD Identification Structural or functional abnormalities of the kidneys for > months, as manifested by either: Urinary albumin-creatinine Ratio > mg/g egfr <6 ml/min/1.7 m2, with or without kidney damage Levey AS, et al: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:289-21, 2 Stage Stages of CKD Description Kidney damage and normal or GFR Kidney damage and Mild GFR Moderate GFR Severe GFR Kidney Failure usually need dialysis GFR (ml/min/1.7 2 ) <1 US Prevalence in Millions.6* 6.* 1.*.7*.+ 26,, *Extrapolation in adults using NHANES , JAMA 16:18-8, 27 +US Renal Data System 28 Annual Data Report Causes of Kidney Failure Cardiovascular Kidney Diabetes 24% Diabetes Hypertension Glomerulonephritis HTN 7% 16% Polycystic Kidney Disease Other 19% 4% CKD Diabetes is the Predominant Cause of Kidney Failure US Renal Data System 2 Annual Data Report DM What Makes CKD Different Cardiovascular disease is the number one killer Chronic Kidney Disease multiplies CVD risk For every CVD risk factor (Diabetes and Hypertension), clinicians must test for CKD What Makes CKD Different The patients are sicker 1. Risk factor levels are higher 2. Control is worse and treatment is more complex. Outcomes are worse 4. Costs are higher With CKD, patient management is different Treatments are available and effective today 4

CKD Risk Factor Levels Are Higher CKD Control is Worse 2 Albuminuria Prevalence, % 2 1 1 4.9 6.9 9.8 14.6 2.

mmhg 1 2 4 Cardiometabolic Syndrome Components* Chen J, et al. Ann Int Med 14:167-174, 24 KEEP N = 44,67. NHANES N = 9,42.

Cardiovascular Mortality Dialysis or Transplantation Adjusted* Cardiovascular Mortality Risk by egfr and albuminuria *adjusted to the incidence rates of a 6 year-old, non- Hispanic white male.

7m2) > 9 Macroalbuminuria Microalbuminuria Normal Am J Epidemiol 28;167(1):1226-124 Death and ESRD, % 4 2 1 CKD Outcomes Are Worse 1.2 Control.7 19. Stage 2 1.1 24. Stage 1. 4.7 Stage 4 19.

5 CKD Risk Factor Levels Are Higher CKD Control is Worse 2 Albuminuria Prevalence, % * Cardiometabolic Syndrome Components: waist > 12 cm in men waist > 88 cm in women fasting glucose > 11 mg/dl HDL-C < 4 mg/dl in men HDL-C < mg/dl in women triglycerides > 14 mg/dl BP > 1/8 mmhg Cardiometabolic Syndrome Components* Chen J, et al. Ann Int Med 14: , 24 KEEP N = 44,67. NHANES N = 9,42. Target blood pressure (JNC 7) DM or CKD: Target blood pressure Systolic: <1 mmhg or Diastolic: <8 mmhg by JNC 7 No DM or CKD: in KEEP and NHANES Systolic: <14 mmhg or Diastolic: <9 mm Hg Cardiovascular Mortality Dialysis or Transplantation Adjusted* Cardiovascular Mortality Risk by egfr and albuminuria *adjusted to the incidence rates of a 6 year-old, non- Hispanic white male. Left Ventricular Hypertrophy Loss of GFR Chronic Kidney Disease Adjusted Incidence Rate (per 1 personyears) 4 2 Microalbuminuria Microalbuminuria Estimated GFR (ml/min/1.7m2) > 9 Macroalbuminuria Microalbuminuria Normal Am J Epidemiol 28;167(1): Death and ESRD, % CKD Outcomes Are Worse 1.2 Control Stage Stage Stage Control GFR 6-89 Absent proteinuria n = 14,22.9 months f/u Stage 2 n = 1, months f/u Stage n = 11, months f/u Stage 4 n = months f/u RED Death Black Dialysis or Kidney Transplantation Keith DS, et al. Arch Int Med 164:69-66, 24 CKD Outcomes Are Worse Incidence of Kidney Failure Healthy People 21 Goal: 217 US Renal Data System 26 Annual Data Report

CKD Costs Are Higher Early Identification Allows More Time for Interventions to Prevent or Delay CKD Progression and Complications

risk reduction: Dyslipidemia management, Tobacco cessation Avoid NSAIDS/Contrast Anemia Nutrition Renal bone disease Vascular

Angiotensin Receptor Blocker Vignette Summary Without Early Evaluation 42-year-old African-American man with Stage CKD Diabetic

There were many opportunities to diagnose and treat CKD over an 18-year course of type-1 diabetes.

6 CKD Costs Are Higher Early Identification Allows More Time for Interventions to Prevent or Delay CKD Progression and Complications CKD 8.7 % of the Medicare population, yet they consumed 24. % of expenditures in 26 ($ billion). CKD is a disease and cost multiplier. US Renal Data System 28 Annual Data Report CKD Intervention: Clinical Action Plan GFR BP<1/8 mm Hg, ACEI/ARB Glycemic control CVD risk reduction: Dyslipidemia management, Tobacco cessation Avoid NSAIDS/Contrast Anemia Nutrition Renal bone disease Vascular access & Transplantation Stage 1-2 >6 ACEI = Angiotensin Converting Enzyme Inhibitor Stage -9 Stage Stage <1 ARB = Angiotensin Receptor Blocker Vignette Summary Without Early Evaluation 42-year-old African-American man with Stage CKD Diabetic Kidney Disease. The course of the illness was likely over several years. There were many opportunities to diagnose and treat CKD over an 18-year course of type-1 diabetes. This patient is now faced with dialysis and transplant preparation. There is a better way! Early identification allows more time for interventions to prevent or delay complications and slow loss of kidney function. ACIP Vaccination Recommendations for the ESRD Patient June 26 Available for download at: 6

7 Early Intervention Can Make a Difference GFR (ml/min/1.7 2 ) 1 1 Kidney Failure Time (years) No Treatment Current Treatment Early Treatment SBP (mm Hg) = 1 mmhg r =.42; P < Untreated -8 HTN Modified from Bakris GL et al. Am J Kidney Dis. 2;6: GFR (ml/min/year) Summary of Studies on CKD Intervention RENAAL, NEJM, 22; IDNT, NEJM, 22, AASK trial, JAMA, 22, AIPRI, NEJM, 1996, MDRD, NEJM, 1994, REIN, Lancet, 1998, ABCD, Diabetes Care (suppl) 2, Kidney Int, 1996, Hypertension, 1997 Evaluations Please visit to fill out your evaluation and post test. Nursing Contact Hours, CME, CHES are available. Thank you! 7

Kidney Disease, Hypertension and Cardiovascular Risk

1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,